Statement of Changes in Beneficial Ownership (4)
2020年2月5日 - 6:16AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
SACHS BRUCE I |
2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA
[
VRTX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/31/2020 |
(Street)
BOSTON, MA 02210
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 1/31/2020 | | M | | 20000 | A | $53.85 | 31210 | D | |
Common Stock | 1/31/2020 | | S(1) | | 1700 | D | $224.02 (2)(3) | 29510 | D | |
Common Stock | 1/31/2020 | | S(1) | | 1858 | D | $224.98 (3)(4) | 27652 | D | |
Common Stock | 1/31/2020 | | S(1) | | 4198 | D | $226.32 (3)(5) | 23454 | D | |
Common Stock | 1/31/2020 | | S(1) | | 5644 | D | $227.01 (3)(6) | 17810 | D | |
Common Stock | 1/31/2020 | | S(1) | | 300 | D | $227.66 (3)(7) | 17510 | D | |
Common Stock | 1/31/2020 | | S(1) | | 600 | D | $228.33 (3)(8) | 16910 | D | |
Common Stock | 1/31/2020 | | S(1) | | 500 | D | $229.90 (3)(9) | 16410 | D | |
Common Stock | 1/31/2020 | | S(1) | | 1200 | D | $230.87 (3)(10) | 15210 | D | |
Common Stock | 1/31/2020 | | S(1) | | 1200 | D | $232.04 (3)(11) | 14010 | D | |
Common Stock | 1/31/2020 | | S(1) | | 1800 | D | $233.13 (3)(12) | 12210 | D | |
Common Stock | 1/31/2020 | | S(1) | | 900 | D | $234.15 (3)(13) | 11310 | D | |
Common Stock | 1/31/2020 | | S(1) | | 100 | D | $235.40 | 11210 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $53.85 | 1/31/2020 | | M | | | 20000 | (14) | 5/31/2021 | Common Stock | 20000 | $0.00 | 0 | D | |
Explanation of Responses: |
(1) | Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. |
(2) | Open market sales reported on this line occurred at a weighted average price of $224.02 (range $223.58 to $224.40). |
(3) | Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
(4) | Open market sales reported on this line occurred at a weighted average price of $224.98 (range $224.66 to $225.21). |
(5) | Open market sales reported on this line occurred at a weighted average price of $226.32 (range $225.62 to $226.60). |
(6) | Open market sales reported on this line occurred at a weighted average price of $227.01 (range $226.70 to $227.59). |
(7) | Open market sales reported on this line occurred at a weighted average price of $227.66 (range $227.62 to $227.70). |
(8) | Open market sales reported on this line occurred at a weighted average price of $228.33 (range $227.97 to $228.78). |
(9) | Open market sales reported on this line occurred at a weighted average price of $229.90 (range $229.16 to $230.12). |
(10) | Open market sales reported on this line occurred at a weighted average price of $230.87 (range $230.32 to $231.23). |
(11) | Open market sales reported on this line occurred at a weighted average price of $232.04 (range $231.45 to $232.42). |
(12) | Open market sales reported on this line occurred at a weighted average price of $233.13 (range $232.69 to $233.49). |
(13) | Open market sales reported on this line occurred at a weighted average price of $234.15 (range $233.77 to $234.66). |
(14) | Fully vested. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
SACHS BRUCE I C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210 | X |
|
|
|
Signatures
|
/s/ Omar White, Attorney-in-Fact | | 2/4/2020 |
**Signature of Reporting Person | Date |
Vertex Pharmaceuticals (NASDAQ:VRTX)
過去 株価チャート
から 6 2024 まで 7 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
過去 株価チャート
から 7 2023 まで 7 2024